Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exatecan SCHEMBL29548714 | 1.00 | TOP1 (0.59) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7163616 | 1.00 | TOP1 (0.59) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL31615015 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7249645 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7255477 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL25349032 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL2512959 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL23471938 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL26320 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL29351332 | 0.99 | TOP1 (0.60) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109460-A1 | Medicinal composition containing camptothecin derivative and ph regulating agent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-12 | — | — | US | claimed |
| EP-1310254-A1 | MEDICINAL COMPOSITIONS CONTAINING CAMPTOTHECIN DERIVATIVE AND PH REGULATING AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-14 | — | — | EP | claimed |
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20030109460-A1 | Medicinal composition containing camptothecin derivative and ph regulating agent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-12 | — | — | US | disclosed |
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1310254-A1 | MEDICINAL COMPOSITIONS CONTAINING CAMPTOTHECIN DERIVATIVE AND PH REGULATING AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6552197-B2 | Condensed-hexacyclic compounds and a process therefor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-6504029-B1 | Reacting methanesulfonic acid with camptothecins, then crystallization and isomerization to obtain hydrophylic, filterable and soluble isomers | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-07 | — | — | US | disclosed |
| US-20010034446-A1 | Condensed-hexacyclic compounds and a process therefor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-10-25 | — | — | US | disclosed |
| EP-0737686-B1 | Camthothecin derivative with antitumor activity | DAIICHI SEIYAKU CO (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0737686-A1 | Camthothecin derivative with antitumour activity | Daiichi Pharmaceutical Co., Ltd. (JP) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034446-A1 | Condensed-hexacyclic compounds and a process therefor | CYP51A1, CYP4F11, FAR1 | TOP1 1597/4885MEN1 496/4885KMT2A 4311/4885 |
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | CD44, MUC1, HGFAC | TOP1 3747/4885MEN1 72/4885KMT2A 3113/4885 |
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | CD44, MUC1, HGFAC | TOP1 3747/4885MEN1 72/4885KMT2A 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.